Rein Therapeutics, Inc. Common Stock
Here’s whether Rein Therapeutics, Inc. Common Stock (RNTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+6.58% over 10 days). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -37.2%; 3-month momentum negative (-20.2%); rising volume on a downtrend (distribution, 2.54x avg). Currently 57.1% off its 52-week high. Score: -4/7.
RNTX is trading below its 200-day MA ($1.31) — a key warning sign the longer-term trend is under pressure. An RSI of 32.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -37.2% compares to +27.9% for SPY (trailed the market by 65.1%). The current 57.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.